{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:35:01Z","timestamp":1762641301577,"version":"build-2065373602"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 MH123396"],"award-info":[{"award-number":["R01 MH123396"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K24 AI167805"],"award-info":[{"award-number":["K24 AI167805"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003323","name":"ANRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Maladies Infectieuses Emergentes"},{"name":"French Society of Infectious Diseases"},{"DOI":"10.13039\/100032692","name":"SPILF","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100032692","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100032692","name":"Soci\u00e9t\u00e9 de Pathologie Infectieuse de Langue Fran\u00e7aise","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100032692","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to assess eligibility for long-acting injectable (LAI) cabotegravir\/rilpivirine among people with HIV (PWH), identify factors associated with initiation and examine provider prescribing patterns in an urban academic clinic in the USA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort analysis among PWH at the University of Chicago HIV clinic from 1 January 2021 to 31 May 2023. Eligibility criteria for LAI cabotegravir\/rilpivirine included HIV-1 RNA &amp;lt;50\u2005copies\/mL for \u22653\u2005months, no active hepatitis B, no resistance to rilpivirine or cabotegravir and no treatment failure history. Logistic regression identified factors associated with initiation among eligible PWH as well as prescribing patterns of providers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 657 PWH, 413 (63%) were eligible for LAI cabotegravir\/rilpivirine. Median age was 45, 33% were women, 84% Black, 70% had permanent housing, 52% employed, 56% on Medicaid, 9% had active substance use and 26% had psychiatric comorbidities. Among those eligible, 64 PWH (15%) initiated LAI cabotegravir\/rilpivirine. In multivariate analysis, younger age was the only factor associated with LAI cabotegravir\/rilpivirine initiation [OR 0.96, 95% CI (0.94, 0.99), P\u200a=\u200a0.01]. Prescribing patterns varied widely among the 13 providers, with initiation rates ranging from 0% to 33% (P\u200a&amp;lt;\u200a0.001). Two providers, covering 40% of eligible patients, were responsible for 70% of initiations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In our urban HIV clinic, 63% of PWH were eligible for LAI cabotegravir\/rilpivirine, and 15% initiated it within 2.5 years post-approval. Age and provider patterns significantly influenced LAI cabotegravir\/rilpivirine uptake. Understanding factors driving LAI cabotegravir\/rilpivirine uptake is key to expanding its reach.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf346","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T11:53:29Z","timestamp":1756986809000},"page":"3092-3100","source":"Crossref","is-referenced-by-count":0,"title":["Eligibility and factors associated with long-acting injectable cabotegravir-rilpivirine initiation in an urban academic HIV clinic"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1267-4347","authenticated-orcid":false,"given":"Geoffroy","family":"Liegeon","sequence":"first","affiliation":[{"name":"Department of Medicine, The University of Chicago , Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleanor","family":"Friedman","sequence":"additional","affiliation":[{"name":"Department of Medicine, The University of Chicago , Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Kaperak","sequence":"additional","affiliation":[{"name":"Department of Medicine, The University of Chicago , Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Djuricich","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The University of Chicago , Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Dawdani","sequence":"additional","affiliation":[{"name":"Department of Medicine, The University of Chicago , Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Plotkin","sequence":"additional","affiliation":[{"name":"Department of Medicine, The University of Chicago , Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5125-7808","authenticated-orcid":false,"given":"Jessica","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Department of Medicine, The University of Chicago , Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8557-4465","authenticated-orcid":false,"given":"Aniruddha","family":"Hazra","sequence":"additional","affiliation":[{"name":"Department of Medicine, The University of Chicago , Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8598-2191","authenticated-orcid":false,"given":"Katerina A","family":"Christopoulos","sequence":"additional","affiliation":[{"name":"Division of HIV, ID, and Global Medicine, University of California San Francisco , San Francisco, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A","family":"Schneider","sequence":"additional","affiliation":[{"name":"Department of Medicine, The University of Chicago , Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moira C","family":"McNulty","sequence":"additional","affiliation":[{"name":"Department of Medicine, The University of Chicago , Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"volume-title":"Cabenuva","year":"2021","key":"2025110817253277800_dkaf346-B1"},{"key":"2025110817253277800_dkaf346-B2","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.1007\/s12325-021-01883-8","article-title":"Real-world adherence to antiretroviral therapy among HIV-1 patients across the United States","volume":"38","author":"McComsey","year":"2021","journal-title":"Adv Ther"},{"key":"2025110817253277800_dkaf346-B3","doi-asserted-by":"publisher","first-page":"e766","DOI":"10.1016\/S2352-3018(21)00265-4","article-title":"Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: a multiregional, retrospective cohort study in 31 countries","volume":"8","author":"Han","year":"2021","journal-title":"Lancet HIV"},{"key":"2025110817253277800_dkaf346-B4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.coviro.2016.03.004","article-title":"Current status and prospects of HIV treatment","volume":"18","author":"Cihlar","year":"2016","journal-title":"Curr Opin Virol"},{"key":"2025110817253277800_dkaf346-B5","article-title":"Monitoring selected national HIV prevention and care objectives by using HIV surveillance data\u2014United States and 6 dependent areas, 2021","volume":"28","author":"Centers for Disease Control and Prevention","year":"2023","journal-title":"HIV Surveillance Supplemental Report"},{"key":"2025110817253277800_dkaf346-B6","doi-asserted-by":"publisher","first-page":"ofy035","DOI":"10.1093\/ofid\/ofy035","article-title":"Degree of housing instability shows independent \u2018dose-response\u2019 with virologic suppression rates among people living with Human Immunodeficiency Virus","volume":"5","author":"Clemenzi-Allen","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2025110817253277800_dkaf346-B7","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/QAI.0000000000001874","article-title":"The association of unmet needs with subsequent retention in care and HIV suppression among hospitalized patients with HIV who are out of care","volume":"80","author":"Dandachi","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025110817253277800_dkaf346-B8","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1097\/QAD.0000000000003005","article-title":"Depression and HIV viral nonsuppression among people engaged in HIV care in an urban clinic, 2014\u20132019","volume":"35","author":"Lesko","year":"2021","journal-title":"AIDS"},{"key":"2025110817253277800_dkaf346-B9","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1097\/QAD.0000000000002595","article-title":"Internalized HIV stigma predicts subsequent viremia in US HIV patients through depressive symptoms and antiretroviral therapy adherence","volume":"34","author":"Christopoulos","year":"2020","journal-title":"AIDS"},{"key":"2025110817253277800_dkaf346-B10","first-page":"403","article-title":"The impact of acculturation on Latinos\u2019 perceived barriers to HIV primary care","volume":"18","author":"Rajabiun","year":"2008","journal-title":"Ethn Dis"},{"key":"2025110817253277800_dkaf346-B11","doi-asserted-by":"publisher","first-page":"ofab330","DOI":"10.1093\/ofid\/ofab330","article-title":"Social determinants of health and care outcomes among people with HIV in the United States","volume":"8","author":"Menza","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2025110817253277800_dkaf346-B12","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1089\/heq.2020.0105","article-title":"Medical mistrust and adherence to care among a heterogeneous cohort of women living with HIV, followed in a large, U.S. Safety Net Clinic","volume":"5","author":"Duthely","year":"2021","journal-title":"Health Equity"},{"key":"2025110817253277800_dkaf346-B13","doi-asserted-by":"publisher","first-page":"23259582211009011","DOI":"10.1177\/23259582211009011","article-title":"The promise of improved adherence with long-acting antiretroviral therapy: what are the data?","volume":"20","author":"Scarsi","year":"2021","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"2025110817253277800_dkaf346-B14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1089\/aid.2020.0126","article-title":"The LAIs are coming! Implementation science considerations for long-acting injectable antiretroviral therapy in the United States: a scoping review","volume":"37","author":"Kanazawa","year":"2021","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2025110817253277800_dkaf346-B15","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1007\/s10461-024-04315-0","article-title":"Acceptability of long-acting injectable antiretroviral therapy among people with HIV receiving care at three Ryan White funded clinics in the United States","volume":"28","author":"Erguera","year":"2024","journal-title":"AIDS Behav"},{"key":"2025110817253277800_dkaf346-B16","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s43058-023-00506-3","article-title":"Assessing readiness to implement long-acting injectable HIV antiretroviral therapy: provider and staff perspectives","volume":"4","author":"Koester","year":"2023","journal-title":"Implement Sci Commun"},{"key":"2025110817253277800_dkaf346-B17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12913-021-06214-9","article-title":"Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials","volume":"21","author":"Mantsios","year":"2021","journal-title":"BMC Health Serv Res"},{"key":"2025110817253277800_dkaf346-B18","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1080\/09540121.2020.1764906","article-title":"Acceptability and preferences for long-acting antiretroviral formulations among people with HIV infection","volume":"33","author":"Dandachi","year":"2021","journal-title":"AIDS Care"},{"key":"2025110817253277800_dkaf346-B19","doi-asserted-by":"publisher","first-page":"e0190487","DOI":"10.1371\/journal.pone.0190487","article-title":"Experiences with long acting injectable ART: a qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain","volume":"13","author":"Kerrigan","year":"2018","journal-title":"PLoS One"},{"key":"2025110817253277800_dkaf346-B20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/09540121.2020.1742869","article-title":"Perspectives of injectable long acting antiretroviral therapies for HIV treatment or prevention: understanding potential users\u2019 ambivalences","volume":"32","author":"Carillon","year":"2020","journal-title":"AIDS Care"},{"key":"2025110817253277800_dkaf346-B21","doi-asserted-by":"publisher","first-page":"e26006","DOI":"10.1002\/jia2.26006","article-title":"Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study","volume":"25","author":"Garris","year":"2022","journal-title":"J Int AIDS Soc"},{"key":"2025110817253277800_dkaf346-B22","doi-asserted-by":"publisher","first-page":"e26003","DOI":"10.1002\/jia2.26003","article-title":"Perspectives of healthcare providers on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation-effectiveness study (CUSTOMIZE)","volume":"25","author":"Czarnogorski","year":"2022","journal-title":"J Int AIDS Soc"},{"key":"2025110817253277800_dkaf346-B23","doi-asserted-by":"publisher","first-page":"ofac293","DOI":"10.1093\/ofid\/ofac293","article-title":"Are patients and their providers talking about long-acting injectable antiretroviral therapy? Penetration into clinical encounters at three U.S. care sites","volume":"9","author":"Christopoulos","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025110817253277800_dkaf346-B24","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/j.1525-1497.2004.30418.x","article-title":"Better physician-patient relationships are associated with higher reported adherence to antiretroviral therapy in patients with HIV infection","volume":"19","author":"Schneider","year":"2004","journal-title":"J Gen Intern Med"},{"key":"2025110817253277800_dkaf346-B25","doi-asserted-by":"publisher","first-page":"969","DOI":"10.7326\/M23-0788","article-title":"Demonstration project of long-acting antiretroviral therapy in a diverse population of people with HIV","volume":"176","author":"Gandhi","year":"2023","journal-title":"Ann Intern Med"},{"key":"2025110817253277800_dkaf346-B26","doi-asserted-by":"publisher","first-page":"e645","DOI":"10.1093\/cid\/ciac631","article-title":"First demonstration project of long-acting injectable antiretroviral therapy for persons with and without detectable Human Immunodeficiency Virus (HIV) Viremia in an Urban HIV Clinic","volume":"76","author":"Christopoulos","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025110817253277800_dkaf346-B27","doi-asserted-by":"publisher","first-page":"ofac455","DOI":"10.1093\/ofid\/ofac455","article-title":"Early experience implementing long-acting injectable cabotegravir\/rilpivirine for Human Immunodeficiency Virus-1 treatment at a ryan white-funded clinic in the US South","volume":"9","author":"Collins","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025110817253277800_dkaf346-B28","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/hiv.13647","article-title":"Real-world use of long-acting cabotegravir and rilpivirine: 12-month results of the inJectable Antiretroviral therapy feasiBility Study (JABS)","volume":"25","author":"John","year":"2024","journal-title":"HIV Med"},{"key":"2025110817253277800_dkaf346-B29","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1089\/apc.2023.0250","article-title":"Implementation of a pharmacist-led, long-acting, injectable cabotegravir\/rilpivirine program for HIV-1 at health system-based clinics in the New York Metropolitan Area","volume":"38","author":"Nguyen","year":"2024","journal-title":"AIDS Patient Care STDS"},{"author":"Centers for Disease Control and Prevention","key":"2025110817253277800_dkaf346-B30"},{"key":"2025110817253277800_dkaf346-B31","doi-asserted-by":"publisher","first-page":"ofaf094","DOI":"10.1093\/ofid\/ofaf094","article-title":"Early experience and effectiveness of long-acting injectable cabotegravir and rilpivirine in a South Side Chicago HIV Clinic","volume":"12","author":"Liegeon","year":"2025","journal-title":"Open Forum Infect Dis"},{"year":"2024","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents.","key":"2025110817253277800_dkaf346-B32"},{"key":"2025110817253277800_dkaf346-B33","doi-asserted-by":"publisher","first-page":"ofae087","DOI":"10.1093\/ofid\/ofae087","article-title":"Low uptake of long-acting injectables in the first 2.5 years following approval among a cohort of people living with HIV","volume":"11","author":"Manghani","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2025110817253277800_dkaf346-B34","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1177\/09564624241289998","article-title":"Characterizing long-acting injectable antiretroviral therapy eligibility and initiation at a safety net academic medical center in the southeastern United States","volume":"36","author":"Rutstein","year":"2025","journal-title":"Int J STD AIDS"},{"key":"2025110817253277800_dkaf346-B35","doi-asserted-by":"publisher","first-page":"4970","DOI":"10.1002\/jmv.27890","article-title":"Are we ready for long-acting? A feasibility evaluation of long-acting cabotegravir-rilpivirine in clinical practice","volume":"94","author":"Borghetti","year":"2022","journal-title":"J Med Virol"},{"author":"Eron","key":"2025110817253277800_dkaf346-B36"},{"key":"2025110817253277800_dkaf346-B37","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1097\/QAD.0000000000003446","article-title":"Single-center experience evaluating and initiating people with HIV on long-acting cabotegravir\/rilpivirine","volume":"37","author":"Hill","year":"2023","journal-title":"AIDS"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/11\/3092\/64344799\/dkaf346.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/11\/3092\/64344799\/dkaf346.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:25:39Z","timestamp":1762640739000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/11\/3092\/8261409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":37,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,9,22]]},"published-print":{"date-parts":[[2025,11,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf346","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,9,22]]}}}